

Supplemental Table 2. Baseline characteristics: 9 injections vs <9 injections

Item/Category	9 Injections		<9 Injections	
	OBI-822 (N=104)	Placebo (N=64)	OBI-822 (N=120)	Placebo (N=60)
IWRS 4-Combined Strata, n (%)				
Hormone non-user with disease	18 (17)	17 (27)	55 (46)	25 (42)
Hormone non-use without disease	8 (8)	3 (5)	3 (3)	3 (5)
Hormone user with disease	70 (67)	38 (59)	59 (49)	30 (50)
Hormone user without disease	8 (8)	6 (9)	3 (3)	2 (3)
No. of Progressions After Metastatic Diagnosis, n (%)				
0	72 (69)	43 (67)	65 (54)	34 (57)
1	25 (24)	20 (31)	42 (35)	17 (28)
2	6 (6)	1 (2)	13 (11)	9 (15)
3	1 (1)	0 (0)	0 (0)	0 (0)
Molecular Subtypes, n (%)				
ER+ and/or PR+ and HER2-	84 (81)	51 (80)	77 (64)	33 (55)
Triple negative	9 (9)	5 (8)	19 (16)	12 (20)
HER2+	11 (11)	8 (13)	24 (20)	15 (25)
Globo H Expression, n (%)				
0	25 (33)	14 (32)	19 (23)	11 (28)
1+	24 (32)	15 (34)	33 (40)	15 (38)
2+	13 (17)	6 (14)	14 (17)	4 (10)
3+	14 (18)	9 (21)	17 (20)	10 (25)
Not done	28	20	37	20
Time From First BC to Day 1 (mo)				
Mean (SD)	65 (57)	75 (76)	62 (56)	49 (38)
Median (min, max)	53 (3, 307)	48 (5, 390)	48 (5, 275)	40 (5, 152)
Time From First Metastatic Diagnosis to Day 1 (mo)				
Mean (SD)	20 (19)	19 (20)	17 (13)	16 (10)
Median (min, max)	12 (3, 87)	14 (3, 151)	12 (1, 74)	12 (4, 39)
Time From Last MBC Progression to Day 1 (mo)				
N	32	21	55	26
Mean (SD)	12 (9)	10 (5)	8 (4)	8 (5)
Median (min, max)	10 (4, 36)	9 (1, 20)	7 (1, 22)	7 (1, 25)
Time From Last Anti-Cancer Treatment to Day 1 (day)				
N	88	59	114	55
Mean (SD)	175 (286)	182 (212)	113 (147)	101 (128)
Median (min, max)	69 (28, 1545)	116 (12, 1219)	55 (26, 1005)	63 (28, 689)
ECOG Performance Status, n (%)				
0	79 (76)	52 (81)	86 (72)	40 (67)
1	25 (24)	12 (19)	33 (28)	20 (33)
Not done	0	0	1	0
Stage at Initial BC Diagnosis				
Stage 0	1 (1)	0 (0)	0 (0)	0 (0)
Stage I	15 (14)	4 (6)	15 (13)	13 (22)
Stage IIa	17 (16)	11 (17)	27 (23)	6 (10)
Stage IIb	13 (13)	7 (11)	7 (6)	5 (8)
Stage IIIa	12 (12)	6 (9)	16 (13)	9 (15)
Stage IIIb	2 (2)	2 (3)	2 (2)	1 (2)
Stage IIIc	7 (7)	9 (14)	7 (6)	7 (12)
Stage IV	30 (29)	19 (30)	42 (35)	18 (30)
Stage unknown	7 (7)	6 (9)	4 (3)	1 (2)

BC, breast cancer; ECOG, Eastern Cooperative Oncology Group; ER+, estrogen receptor-positive; HER2-, human epidermal growth factor receptor 2-negative; HER2+, human epidermal growth factor receptor 2-positive; IWRS, interactive Web response system; MBC, metastatic breast cancer; PR+, progesterone receptor-positive; SD, standard deviation.